Sign Up Today and Learn More About Biosplice Therapeutics Stock
Invest in or calculate the value of your shares in Biosplice Therapeutics or other pre-IPO companies through EquityZen's platform.
Biosplice Therapeutics Stock (BITH)
Tissue-Level Regeneration
About Biosplice Therapeutics Stock
Founded
2008
Headquarters
San Diego, CA, US
Total Funding
658M
Industries
Software, Artificial Intelligence, Data and Analytics
Samumed is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. Samumed adopted a fresh operating philosophy from the beginning — one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health.
Biosplice Therapeutics Press Mentions
Stay in the know about the latest news on Biosplice Therapeutics
Biosplice Announces Upcoming Presentation of Successful OA-07 Phase 3 Long-Term Structure and Pain & Function ...
globenewswire • Jun 26, 2024
Biosplice Announces Collaboration with Novo Nordisk in Diabetes
globenewswire • Jun 26, 2024
Biosplice Therapeutics discovers DYRK1A inhibitors
bioworld • Jun 01, 2024
Biosplice's Oral Presentation at WCO 2024 | Biosplice Therapeutics posted on the topic
linkedin • May 23, 2024
Biosplice Announces Upcoming Presentation of Successful OA-07 Phase 3 Long-Term Structure and Pain & Function ...
finance • May 23, 2024
Investors in Biosplice Therapeutics
Discover investors in Biosplice Therapeutics stock and explore their portfolio companies
Biosplice Therapeutics Management
Leadership team at Biosplice Therapeutics
Chief Executive Officer
Samikoglu Cevdet
Chief Financial Officer
Horsley Erich
Join now and verify your accreditation status to gain access to:
- Biosplice Therapeutics current valuation
- Biosplice Therapeutics stock price
- Available deals in Biosplice Therapeutics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Biosplice Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Biosplice Therapeutics through EquityZen funds. These investments are made available by existing Biosplice Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Biosplice Therapeutics stock?
Shareholders can sell their Biosplice Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
